Jason Feuerman, MD
Ophthalmology · Austin, TXNPI 1205147634
Payments from drug & device makers
Across 102 payments — averaging $40.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson Surgical Vision, Inc.$1K
- AbbVie$684
- Rxsight Inc$348
- Alcon$295
- Biotissue Holdings Inc.$230
- Harrow Eye, LLC$144
- plus $1K from 18 others
What the payments were for
- Consulting fees$75018%
- Food & beverage$3,34582%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson Surgical Vision, Inc. | 9 | $1,264 |
| AbbVie | 24 | $684 |
| Rxsight Inc | 4 | $348 |
| Alcon | 16 | $295 |
| Biotissue Holdings Inc. | 2 | $230 |
| Harrow Eye, LLC | 7 | $144 |
| Genentech USA, Inc. | 1 | $141 |
| Regeneron | 1 | $135 |
| Mallinckrodt Enterprises LLC | 2 | $125 |
| Novartis | 6 | $115 |
| Amgen | 6 | $106 |
| Bausch & Lomb Americas Inc. | 5 | $104 |
| Oyster Point Pharma, Inc. | 3 | $66 |
| Dompe US, Inc. | 2 | $56 |
| Ocular Therapeutix, Inc. | 3 | $52 |
| Sun Pharmaceutical Industries Inc. | 1 | $42 |
| Carl Zeiss Meditec, Inc. | 1 | $36 |
| Tarsus Pharmaceuticals, Inc. | 2 | $36 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $28 |
| Mallinckrodt Hospital Products Inc. | 1 | $25 |
| Rayner Intraocular Lenses Limited | 1 | $22 |
| Tearlab Corp | 1 | $15 |
| Thea Pharma Inc. | 1 | $15 |
| Shire North American Group Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tecnis Symfony IOL$750
- RXSIGHT CONTACT LENS$244
- RXSIGHT INJECTOR CARTRIDGE$244
- RXSIGHT INJECTOR HANDPIECE$244
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$244
- Prokera$230
- AmnioGraft$230
- VABYSMO$141
- EYLEA$135
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$127
- ACTHAR$119
- LIGHT ADJUSTABLE LENS (LAL)$117
- Tecnis Simplicity$117
- OZURDEX$106
- AmnioGuard$106
- Tecnis Multifocal Family of 1-piece IOLS$101
How this compares
$4,095 in reported general payments places this provider in the 65th percentile of 1,355 ophthalmology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 41 | $39,155 |
| XiidraLifitegrast | 30 | $19,540 |
| Cyclosporine | 44 | $13,299 |
| Prednisolone Acetate | 248 | $8,230 |
| LumiganBimatoprost | 16 | $6,598 |
| RocklatanNetarsudil Mesylat/Latanoprost | 19 | $6,154 |
| Fluorometholone | 79 | $5,021 |
| Latanoprost | 421 | $3,067 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 13 | $2,402 |
| CombiganBrimonidine Tartrate/Timolol | 11 | $2,358 |
| Loteprednol Etabonate | 22 | $2,074 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 105 | $1,943 |
| MoxifloxacinMoxifloxacin Hcl | 71 | $1,297 |
| ValacyclovirValacyclovir Hcl | 24 | $972 |
| Timolol Maleate | 103 | $939 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $684 | $48,11068 claims |
| Bausch & Lomb Americas Inc.Xiidra | $104 | $19,54030 claims |
| AlconSimbrinza | $295 | $2,40213 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $28 | $2,07422 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,355 ophthalmology providers in Texas.
Other ophthalmology in Austin
- Chirag JhaveriAustin$9.4M
- Robert WongAustin$6.6M
- Fuad MakkoukAustin$6.6M
- Shelley GhafooriAustin$2.9M
- Thomas WaltersAustin$2.4M
- Philip StoreyAustin$2.1M
- Saradha ChexalAustin$1.8M
- James DoonerAustin$556K
- Charles WykoffBellaire$73.4M
- David BrownHouston$51.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.